Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Northwestern University
Barbara Ann Karmanos Cancer Institute
Wake Forest University Health Sciences
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Rutgers, The State University of New Jersey